Apixaban: Indications, Dosing, Contraindications, and Reversal
Apixaban is a direct factor Xa inhibitor indicated for stroke prevention in nonvalvular atrial fibrillation, VTE prophylaxis after hip/knee replacement, and treatment/secondary prevention of DVT/PE, with specific dose-reduction criteria based on age, weight, and renal function for atrial fibrillation, and andexanet alfa as the preferred reversal agent for life-threatening bleeding. 1
Indications
Apixaban has three FDA-approved indications 1:
- Stroke prevention in nonvalvular atrial fibrillation - Reduces risk of stroke and systemic embolism
- VTE prophylaxis - Following hip or knee replacement surgery
- VTE treatment and secondary prevention - For acute DVT/PE treatment and prevention of recurrence
Critical contraindications include active pathological bleeding and severe hypersensitivity to apixaban. Additionally, apixaban is not recommended for patients with prosthetic heart valves or triple-positive antiphospholipid syndrome 1.
Dosing Regimens
Atrial Fibrillation
Standard dose: 5 mg twice daily 1
Reduced dose: 2.5 mg twice daily when patients meet at least 2 of the following criteria 2, 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
The 2024 ACC/AHA/ACCP/HRS guidelines confirm this dosing applies across all renal function levels, including CrCl 15-30 mL/min and even patients on dialysis 2. This is notably different from other DOACs - dabigatran is contraindicated in dialysis, and edoxaban is contraindicated when CrCl >95 mL/min 2.
VTE Prophylaxis (Hip/Knee Replacement)
2.5 mg twice daily - no dose adjustment needed 1
Acute VTE Treatment
10 mg twice daily for 7 days, then 5 mg twice daily 1
Important caveat: No renal dose adjustments are recommended for VTE treatment, even in severe renal impairment 2, 3. This differs from the atrial fibrillation indication and represents a common source of prescribing confusion.
Secondary VTE Prevention
2.5 mg twice daily after completing initial treatment course 1
Perioperative Management
When interrupting apixaban for surgery (CrCl >25 mL/min) 2:
- Low bleeding risk procedures: Hold for 1 full day before surgery
- High bleeding risk procedures: Hold for 2 full days before surgery
Critical timing detail: "1 day" means one full day without medication before the procedure day. For example, if taking apixaban at 8 PM and surgery is at 8 AM, holding for "1 day" means 36 hours will have elapsed since the last dose 2.
For patients with CrCl <25 mL/min, limited data exist - consider holding an additional 1-3 days, especially for high-risk procedures 2.
Reversal Options
Life-Threatening Bleeding or Emergency Surgery
Andexanet alfa is the licensed specific reversal agent for apixaban (and rivaroxaban), approved since 2019 for major hemorrhage 4. The 2024 ISTH guidance specifies andexanet alfa should be used for 4:
- Life-threatening bleeding (intracranial hemorrhage, expanding/uncontrollable bleeding)
- Bleeding in critical organs or closed spaces
- Urgent/emergency surgery with high bleeding risk that cannot be delayed (e.g., neurosurgery)
Andexanet alfa should NOT be used for 4:
- Elective surgery
- GI bleeds controllable by local measures
- High drug levels without bleeding
- Procedures that can be delayed for drug clearance
Recent data from 2022 shows that periprocedural andexanet alfa achieved excellent or good hemostasis in 78.9% of patients requiring urgent procedures, with significant reductions in PT and anti-Xa levels post-reversal 5.
Alternative Hemostatic Measures
When andexanet alfa is unavailable, prothrombin complex concentrate (PCC) may be considered, though it is not licensed for specific DOAC reversal 4. PCC should only be used when specific antidotes are unavailable or in cases of dilutional coagulopathy from massive blood loss 4.
Tranexamic acid may be used when hyperfibrinolysis is suspected and other therapies have failed 4.
Laboratory Monitoring
Routine monitoring is not required 1, 6. However, when quantification is needed 4:
- Calibrated chromogenic anti-Xa assays are preferred for apixaban levels
- Heparin-calibrated anti-Xa assays show acceptable correlation between 30-100 ng/mL but are unreliable outside this range
- Clinically relevant thresholds: 30 ng/mL and 50 ng/mL 4
- PT and aPTT may be prolonged but lack sensitivity for clinical decisions 4
A 2024 case report demonstrated that apixaban levels can remain detectable for >10 days in elderly patients with chronic kidney disease, emphasizing the utility of anti-Xa monitoring in specific circumstances like perioperative planning 7.
Common Prescribing Pitfalls
Inappropriate dose reduction is prevalent: A 2026 Australian audit found that 41% of patients newly initiated on apixaban 2.5 mg for atrial fibrillation received potentially inappropriate doses 8. The most common error is reducing the dose when only one criterion is met instead of the required two criteria.
VTE dosing confusion: Clinicians sometimes inappropriately apply atrial fibrillation dose-reduction criteria to VTE treatment, where no renal adjustments are recommended 3.
Drug interactions requiring dose adjustment 1:
- Combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): Reduce apixaban dose or avoid
- Combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Avoid concomitant use
Pharmacokinetics
Apixaban has a half-life of approximately 12 hours, with peak concentration at 3-4 hours post-dose 6. Bioavailability is ~50%, and elimination occurs via multiple pathways: 27% renal excretion, with the remainder through metabolism, biliary excretion, and direct intestinal excretion 6. This multiple-pathway elimination explains why apixaban can be used across a broader range of renal function compared to other DOACs.